Just announcing some agreements to finance strategic growth priorities has given a trigger to buyers in pushing Acutus Medical (NASDAQ: AFIB) by 45% in the premarket. This price move is temporary and can fade anytime when other stocks announce any valuable news.
AFIB is still in a negative area of EPS and has not reached enough revenue to cover massive expenses. It is moving in a roller-coaster pattern that is fueled by corporate and innovational updates. Investing in AFIB can make you rich if it starts making profits or lose insignificant money in case of a worse scenario.
There are hundreds of cash-burning healthcare stocks that jump and fall mostly due to clinical trials. If you are ready to gamble just throw some thousands in them and see which will skyrocket in weeks.